MXPA99011821A - Metodo terapeutico para manejo de diabetes mellitus. - Google Patents
Metodo terapeutico para manejo de diabetes mellitus.Info
- Publication number
- MXPA99011821A MXPA99011821A MXPA99011821A MX9911821A MXPA99011821A MX PA99011821 A MXPA99011821 A MX PA99011821A MX PA99011821 A MXPA99011821 A MX PA99011821A MX 9911821 A MX9911821 A MX 9911821A MX PA99011821 A MXPA99011821 A MX PA99011821A
- Authority
- MX
- Mexico
- Prior art keywords
- mammal
- insulin
- tetracycline
- agent
- dimethylamino
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 85
- 238000002560 therapeutic procedure Methods 0.000 title claims description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 170
- 239000008103 glucose Substances 0.000 claims description 109
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 102
- 239000004098 Tetracycline Substances 0.000 claims description 91
- 235000019364 tetracycline Nutrition 0.000 claims description 91
- 102000004877 Insulin Human genes 0.000 claims description 85
- 108090001061 Insulin Proteins 0.000 claims description 85
- 229940125396 insulin Drugs 0.000 claims description 85
- 241000124008 Mammalia Species 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 73
- 229960002180 tetracycline Drugs 0.000 claims description 62
- 229930101283 tetracycline Natural products 0.000 claims description 62
- 239000008280 blood Substances 0.000 claims description 51
- 210000004369 blood Anatomy 0.000 claims description 51
- -1 tetracycline compound Chemical class 0.000 claims description 51
- 150000003522 tetracyclines Chemical class 0.000 claims description 46
- 230000013595 glycosylation Effects 0.000 claims description 39
- 238000006206 glycosylation reaction Methods 0.000 claims description 39
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 39
- 239000003472 antidiabetic agent Substances 0.000 claims description 37
- 208000013016 Hypoglycemia Diseases 0.000 claims description 32
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 230000001575 pathological effect Effects 0.000 claims description 29
- 230000000845 anti-microbial effect Effects 0.000 claims description 27
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 21
- XCCHQGIGHCRZOS-KBKZQPOHSA-N (4as,5as,6s,12ar)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@@](C)(O)[C@@H](C[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)C3)(O)C3=O)C3=C(O)C2=C1O XCCHQGIGHCRZOS-KBKZQPOHSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 15
- 201000001421 hyperglycemia Diseases 0.000 claims description 13
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 12
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 12
- 238000011161 development Methods 0.000 claims description 11
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 claims description 10
- BVFDLIAWTKFZQD-JXVDNWKRSA-N cmt-8 Chemical compound O=C1C2=C(O)C=CC=C2C(C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)C[C@@H]1C2O BVFDLIAWTKFZQD-JXVDNWKRSA-N 0.000 claims description 10
- 229940100389 Sulfonylurea Drugs 0.000 claims description 9
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 9
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 9
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 8
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 8
- 230000003914 insulin secretion Effects 0.000 claims description 7
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical group NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 206010029216 Nervousness Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 4
- 229940040944 tetracyclines Drugs 0.000 description 29
- 238000011282 treatment Methods 0.000 description 27
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 230000007774 longterm Effects 0.000 description 9
- 238000011269 treatment regimen Methods 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 206010010071 Coma Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000017169 kidney disease Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- MWUTTXATIMURBN-VSAOOKSHSA-N (4aS,5aS,6S,12aR)-3,6,10,11-tetrahydroxy-6-methyl-1,12-dioxo-4a,5,5a,12a-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C[C@]1(O)[C@H]2C[C@H]3CC(O)=C(C(N)=O)C(=O)[C@H]3C(=O)C2=C(O)c2c(O)cccc12 MWUTTXATIMURBN-VSAOOKSHSA-N 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 208000003443 Unconsciousness Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000011285 therapeutic regimen Methods 0.000 description 5
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 4
- 102000003746 Insulin Receptor Human genes 0.000 description 4
- 108010001127 Insulin Receptor Proteins 0.000 description 4
- 229960001466 acetohexamide Drugs 0.000 description 4
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 229960001761 chlorpropamide Drugs 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- 229960001381 glipizide Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960002277 tolazamide Drugs 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 208000007976 Ketosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003366 colagenolytic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 108700004049 glycosylated serum Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003509 long acting drug Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011277 treatment modality Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 2
- 206010021519 Impaired healing Diseases 0.000 description 2
- 208000009773 Insulin Coma Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010040576 Shock hypoglycaemic Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000004140 ketosis Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000003421 short acting drug Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940072172 tetracycline antibiotic Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 229940127519 Insulin Receptor Agonists Drugs 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 229940122254 Intermediate acting insulin Drugs 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910003251 Na K Inorganic materials 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229940123452 Rapid-acting insulin Drugs 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000238102 Scylla Species 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- VCROZLOYPNVPSH-DCKQLXEASA-N cmt-5 Chemical compound N1N=C2C3=C(O)C=CC=C3[C@@](C)(O)C3C2=C1[C@]1(O)C(=O)C(C(N)=O)=C(O)CC1C3 VCROZLOYPNVPSH-DCKQLXEASA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 108091007231 endothelial receptors Proteins 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940088991 glucotrol Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000003979 response to food Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009476 short term action Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002782 sympathoadrenal effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940035266 tolinase Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/880,945 US5929055A (en) | 1997-06-23 | 1997-06-23 | Therapeutic method for management of diabetes mellitus |
| PCT/US1998/006927 WO1998058658A1 (en) | 1997-06-23 | 1998-04-08 | Therapeutic method for management of diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA99011821A true MXPA99011821A (es) | 2002-07-02 |
Family
ID=25377455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA99011821A MXPA99011821A (es) | 1997-06-23 | 1998-04-08 | Metodo terapeutico para manejo de diabetes mellitus. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5929055A (https=) |
| EP (1) | EP1017414A4 (https=) |
| JP (1) | JP2002511864A (https=) |
| KR (1) | KR20010020497A (https=) |
| AU (1) | AU744846B2 (https=) |
| CA (1) | CA2294169A1 (https=) |
| IL (1) | IL133643A0 (https=) |
| MX (1) | MXPA99011821A (https=) |
| WO (1) | WO1998058658A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9902721A2 (hu) * | 1997-11-25 | 1999-12-28 | The Procter & Gamble Co. | Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület |
| KR20010073190A (ko) * | 1998-09-28 | 2001-07-31 | 제임스 알. 데니히 | 백내장 형성 억제제 |
| US6914057B1 (en) | 1998-09-28 | 2005-07-05 | The Research Foundation Of State University Of New York | Inhibitor of cataract formation |
| WO2002072146A2 (en) * | 2001-03-12 | 2002-09-19 | Novartis Ag | Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| AU2002256092C1 (en) * | 2001-04-05 | 2009-10-15 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
| FR2826278B1 (fr) * | 2001-06-20 | 2005-03-25 | Lipha | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
| EP1397124B1 (fr) * | 2001-06-20 | 2006-11-29 | Merck Sante | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
| EP2329826A1 (en) | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of multiple sclerosis |
| AU2002359730A1 (en) * | 2001-12-21 | 2003-07-30 | Smithkline Beecham Corporation | Compositions and methods for altering glucose production |
| EP2311799A1 (en) | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
| JP2005526754A (ja) | 2002-03-08 | 2005-09-08 | パラテック ファーマシューティカルズ インコーポレイテッド | アミノメチル置換されたテトラサイクリン化合物 |
| KR101083498B1 (ko) | 2002-03-21 | 2011-11-16 | 파라테크 파마슈티컬스, 인크. | 치환된 테트라시클린 화합물 |
| CA2492273C (en) | 2002-07-12 | 2013-02-05 | Paratek Pharmaceuticals, Inc. | 3, 10, and 12a substituted tetracycline compounds |
| ES2534827T3 (es) | 2003-04-07 | 2015-04-29 | Supernus Pharmaceuticals, Inc. | Formulaciones de tetraciclinas en dosis única diaria |
| CA2531728A1 (en) | 2003-07-09 | 2005-02-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| JP4738333B2 (ja) | 2003-07-09 | 2011-08-03 | パラテック ファーマシューティカルズ インコーポレイテッド | ９−アミノメチルテトラサイクリン化合物のプロドラッグ |
| CA2553510C (en) * | 2004-01-15 | 2012-09-25 | Paratek Pharmaceuticals, Inc. | Aromatic a-ring derivatives of tetracycline compounds |
| EP2269985A3 (en) | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| AU2005299294B2 (en) | 2004-10-25 | 2012-06-07 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
| JP2009502809A (ja) * | 2005-07-21 | 2009-01-29 | パラテック ファーマシューティカルズ インコーポレイテッド | １０−置換テトラサイクリンおよびその使用方法 |
| US20070098763A1 (en) * | 2005-10-11 | 2007-05-03 | Sinnott Robert A | Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health |
| PT2120963T (pt) | 2006-12-21 | 2018-12-17 | Paratek Pharm Innc | Compostos tetraciclina substituídos para tratamento de distúrbios inflamatórios da pele |
| PL2109602T3 (pl) * | 2006-12-21 | 2014-09-30 | Paratek Pharm Innc | Pochodne tetracyliny do leczenia zakażeń bakteryjnych, wirusowych i pasożytniczych |
| JP2010525069A (ja) * | 2007-04-27 | 2010-07-22 | パラテック ファーマシューティカルズ インコーポレイテッド | アミノアルキルテトラサイクリン化合物の合成方法および精製方法 |
| BRPI0823405A2 (pt) * | 2007-07-06 | 2012-12-25 | Paratek Pharmaceuticals, Inc. | mÉtodos para sintetizar compostos de tetraciclina substituÍda |
| TW202216656A (zh) | 2008-05-19 | 2022-05-01 | 美商Ｐｒｔｋ Ｓｐｖ２公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
| PT2323972E (pt) | 2008-08-08 | 2013-10-09 | Tetraphase Pharmaceuticals Inc | Compostos de tetraciclina substituídos com c7-flúor |
| EP2427425B1 (en) | 2009-05-08 | 2017-03-08 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| IN2012DN02502A (https=) | 2009-08-28 | 2015-08-28 | Tetraphase Pharmaceuticals Inc | |
| TWI592390B (zh) | 2010-03-31 | 2017-07-21 | 四相製藥公司 | 聚環狀四環素化合物 |
| BR112015004523B1 (pt) | 2012-08-31 | 2020-08-04 | Tetraphase Pharmaceuticals, Inc | Compostos de tetraciclina, composições farmacêuticas e seus usos |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| AU2015339576B2 (en) | 2014-10-27 | 2020-02-06 | Glytec, Llc | Subcutaneous outpatient management |
| WO2017031440A1 (en) | 2015-08-20 | 2017-02-23 | Aseko, Inc. | Diabetes management therapy advisor |
| CN110582486B (zh) | 2016-10-19 | 2024-01-12 | 四相制药公司 | 艾若威四环素的结晶形式 |
| US12570604B2 (en) | 2018-11-09 | 2026-03-10 | Tetraphase Pharmaceuticals, Inc. | Polymorphic forms of a tetracycline compound and uses thereof |
| WO2020232227A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| US20230165940A1 (en) * | 2020-04-08 | 2023-06-01 | Hoffman Technologies Llc | Methods of treating conditions characterized by insulin deficiency in animals |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985005036A1 (en) * | 1984-04-30 | 1985-11-21 | The Trustees Of Columbia University In The City Of | Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch |
| US5045538A (en) * | 1990-06-28 | 1991-09-03 | The Research Foundation Of State University Of New York | Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines |
| US5321008A (en) * | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
| EP0599397B1 (en) * | 1992-11-17 | 1996-08-28 | The Research Foundation Of State University Of New York | Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes |
| CA2176747A1 (en) * | 1993-11-17 | 1995-05-26 | J. Brice Weinberg | Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases |
| EP0822834A4 (en) * | 1995-04-07 | 2002-09-18 | Einstein Coll Med | RECOMBINANT (BETA) CELL AND ITS USE |
-
1997
- 1997-06-23 US US08/880,945 patent/US5929055A/en not_active Expired - Lifetime
-
1998
- 1998-04-08 JP JP50438999A patent/JP2002511864A/ja not_active Ceased
- 1998-04-08 EP EP98914580A patent/EP1017414A4/en not_active Withdrawn
- 1998-04-08 MX MXPA99011821A patent/MXPA99011821A/es unknown
- 1998-04-08 IL IL13364398A patent/IL133643A0/xx unknown
- 1998-04-08 KR KR1019997012200A patent/KR20010020497A/ko not_active Ceased
- 1998-04-08 CA CA002294169A patent/CA2294169A1/en not_active Abandoned
- 1998-04-08 AU AU68899/98A patent/AU744846B2/en not_active Ceased
- 1998-04-08 WO PCT/US1998/006927 patent/WO1998058658A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1017414A1 (en) | 2000-07-12 |
| WO1998058658A1 (en) | 1998-12-30 |
| IL133643A0 (en) | 2001-04-30 |
| CA2294169A1 (en) | 1998-12-30 |
| KR20010020497A (ko) | 2001-03-15 |
| AU744846B2 (en) | 2002-03-07 |
| JP2002511864A (ja) | 2002-04-16 |
| EP1017414A4 (en) | 2004-10-06 |
| US5929055A (en) | 1999-07-27 |
| AU6889998A (en) | 1999-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5929055A (en) | Therapeutic method for management of diabetes mellitus | |
| US5859037A (en) | Sulfonylurea-glitazone combinations for diabetes | |
| US6498193B2 (en) | Treatment for complications of type 2 diabetes | |
| Lee et al. | Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. | |
| EP1128834B1 (en) | Combinations for diabetes which contain glyburide,troglitazone (and a biguanide) | |
| EP1011673B1 (en) | Novel niddm regimen | |
| Gimbel et al. | Prophylactic intracameral antibiotics during cataract surgery: the incidence of endophthalmitis and corneal endothelial cell loss | |
| US20090317372A1 (en) | Small molecules for the reduction of high blood glucose level | |
| ES2239316T3 (es) | Metodo para el tratamiento de la obesidad usando moduladores de prolactina y dieta. | |
| Hanefeld et al. | Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study | |
| US20240100127A1 (en) | Tirzepatide therapeutic methods | |
| Matsuo | Disappearance of diabetic macular hard exudates after hemodialysis introduction | |
| EP4342476A1 (en) | Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin | |
| Kadhe et al. | Advances in drug delivery of oral hypoglycemic agents | |
| Chantelau et al. | Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration–a case report | |
| Zadok et al. | Combined timolol and pilocarpine vs pilocarpine alone and timolol alone in the treatment of glaucoma | |
| Kogure et al. | Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema | |
| US6355682B1 (en) | Treatment of acute renal failure by administration of N-acetylcysteine | |
| CA2806619A1 (en) | Anti-diabetic compositions and methods | |
| Johnson | Preop Glycemic Control Decreases Infection Risk | |
| Cameron et al. | DIABETIC RETINOPATHY AND CYANCOBALAMIN (VITAMIN B12): A PRELIMINARY REPORT | |
| Bcttman | d&c dropsy, that the nerve head can $ tbtand pressure for a long time, that in this particular typl? Of glaucoma, cdicaI treatment with miotica and EaIin~ purging arc to be used so long as | |
| KR20060130205A (ko) | 비-항균성 테트라사이클린 제제로 대동맥 협착증을치료하는 방법 | |
| Berlin et al. | Comparison of the inhibition of the monoamine oxidase by two reversible IMAO, moclobemide and toloxatone. Study of their effect on memory and vigilance | |
| Makrilakis | Diabetes and old age |